Page URL:

Genetic link to fertility drug response found

5 July 2010
Appeared in BioNews 565

Scientists have discovered a genetic mutation that may make some women less likely to respond to the ovarian stimulating hormones used in fertility treatment. Dr Maria Lalioti and her colleagues from Yale University Medical School, US, reported their findings at the 26th annual meeting of the European Society of Human Reproduction and Embryology in Rome last week.

The genetic variation results in an abnormal receptor that sits on the surface of cells surrounding the developing egg in a woman's ovary. Follicle stimulating hormone (FSH) activates these receptors and promotes the maturation of an egg so it is ready for fertilisation. The hormone is given to woman during fertility treatment to stimulate the production of multiple eggs before undergoing IVF. However, some women fail to adequately respond to the hormone treatment and prior to this study an underlying reason for this was unknown. The mutation identified by the scientists could explain at least some cases and indeed, it was found in two out of five women who had poor responses to treatment.

At the meeting, the question was raised of how such a mutation had been maintained in our genome when it paradoxically hinders reproduction, to which Dr Lalioti responded: 'Our Grandmothers' generation used to reproduce earlier, so in general their fertility was better and that's how a lot of these variants are kept in the population. They may be rare. We are looking at IVF populations, selected because they can't get pregnant, so it is possible to be present in the general population but in a smaller amount. It may not have such a big influence once people try to reproduce earlier, when their ovaries are functioning better'.

This work has important implications for future research and treatment. 'The importance of this finding is that it creates a link between genetic variation and sub-fertility. These women have a normal menstrual cycle and they may present to the fertility centre as patients with unexplained infertility, before their first IVF cycle that would reveal an ovarian stimulation defect,' explained Dr Lalioti.

'Our finding explains why these women have a lower response to FSH. Currently, FSH is the only medication used to stimulate ovarian response, but once other medications are available that can bypass the receptor for FSH, they can be tested on these women. Also, at present we cannot predict if the women would profit from having higher doses of medication, and, in fact, some preliminary data from other groups show the opposite: that lower FSH may be more beneficial'.

Dr Lalioti went on to explain that the next steps were to recruit more patients to more accurately assess the prevalence of the mutation and investigate alternative drugs to FSH, which could promote egg development more effectively in these women. 'In the future, this could lead to personalised treatments for a sub-group of patients', she said.

Researchers discover why some women are sub-fertile and have a poor response to ovarian stimulating hormones
ESHRE |  29 June 2010
22 June 2020 - by Emma Bunting 
Determining when ageing starts, our predicted remaining lifespan, and how long women remain fertile can be predicted from the rate we accumulate mutations as young adults, scientists claim...
19 March 2012 - by Dr Lamiya Mohiyiddeen and Luciano Nardo 
IVF is a complex treatment for infertility requiring costly drugs and carrying significant risk of complications. Part of the procedure aims to stimulate the ovaries to produce more eggs, and conventional methods include a combination of hormones to induce follicle growth, from which eggs are collected...
12 July 2010 - by Victoria Kay 
A US study looking at the relationship between genes known to cause a rare genetic disease has shown that common and rare genetic variants interact to make symptoms more or less severe...
8 March 2010 - by Maren Urner 
The UK supermarket chain Asda is to become the first to sell IVF drugs without profit, saving patients up to £820 per treatment cycle. The move is part of the retailer's bid to become the most competitive pharmacy in the UK....
1 February 2010 - by Dr Marianne Kennedy 
The European Commission has granted approval of ELONVA, a first-in-class drug manufactured by White House Station pharmaceutical company, Merck. ELONVA is used for controlled ovarian stimulation in women embarking on in vitro fertilisation (IVF) treatment for infertility. With this approval, Merck has marketing authorisation for the drug in all EU member states....
7 December 2009 - by Heidi Colleran 
A team of scientists has taken male fertility research a major step forward, with the discovery of how androgenic hormones regulate the production of sperm in the testes of mice. The breakthrough, reported in the journal The Federation of American Societies for Experimental Biology (FASEB), may lead to greater understanding and control of male fertility, including the development of a male contraceptive 'pill', and treatments for infertility....
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.